Opinion|Videos|October 7, 2024
ECOSPOR Trials and Data with Fecal Microbiota Spores, Live-BRPK Oral Capsules (VAS) for C. difficile Infections
Paul Feuerstadt, MD, FACG, AGAF, discusses the key findings from the phase 3 ECOSPOR clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discussion of key findings from the phase 3 clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
- Comparing the two clinical trials, what were some significant differences between them?
Advertisement
Related to this article
The Peggy Lillis Foundation's CEO and Co-founder Christian Lillis discusses the organization's initiatives for C diff month, and offers a glimpse of the upcoming Scientific Symposium they are hosting next week.
Advertisement
Advertisement
Trending on Contagion Live
1
Reports Say US Loses Measles Elimination Status After 26 Years
2
Peggy Lillis Foundation Expands C diff Campaign to Pediatric Population, Survivors
3
Measles Update: November 13, 2026
4
Cefepime-Zidebactam, a Novel Option for AMR Infections
5